Beyond the double-helix: non-canonical nucleic acid structures as drug targets and therapeutics.
Abstract
Nucleic acids adopt a rich repertoire of non-canonical structures beyond the iconic double helix - G-quadruplexes, i-motifs, triplexes, R-loops, Z-DNA/Z-RNA, and junctions - with roles in genome stability, transcription, replication, and translation. Yet the biological evidence for these conformations varies widely, from direct in vivo validation to largely indirect biochemical inference. We organize this review around a distinctive therapeutic duality: non-canonical structures may serve as molecular targets for small molecules, peptides, and nucleic acid-based modulators, while some are also engineered as therapeutic agents in their own right. For each structural class, we critically assess structural principles, biological evidence, and detection methods, explicitly distinguishing direct in vivo validation from cell-based and biochemical observations and noting the limitations of current detection strategies. Comparing translational maturity across classes through the lens of target versus agent, we identify key challenges - structural selectivity, mechanistic attribution, target engagement, and delivery - that must be resolved to fully realize the therapeutic potential of non-canonical nucleic acid structures.